224 related articles for article (PubMed ID: 10071979)
21. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
25. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
[TBL] [Abstract][Full Text] [Related]
26. [The effect and pharmacokinetics of etoposide in patients with primary hepatocellular carcinoma].
Funakoshi S; Aiba K; Dobashi F; Inamoto Y; Hirano A; Tada N; Ogihara A; Fujii T; Kuraishi Y; Yamada T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):165-7. PubMed ID: 8380686
[No Abstract] [Full Text] [Related]
27. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
28. Level of evidence for therapeutic drug monitoring for etoposide after oral administration.
Gerritsen-van Schieveen P; Royer B;
Fundam Clin Pharmacol; 2011 Jun; 25(3):277-82. PubMed ID: 20608987
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
[TBL] [Abstract][Full Text] [Related]
30. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
Li C; Li X; Choi JS
Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
[TBL] [Abstract][Full Text] [Related]
31. Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.
Osby E; Liliemark E; Björkholm M; Liliemark J
Med Oncol; 2001; 18(4):269-75. PubMed ID: 11918453
[TBL] [Abstract][Full Text] [Related]
32. [Hepatic arterial infusion of etoposide in the treatment of primary liver neoplasms].
Yasuda H; Fujino H; Tagawa K; Unuma T
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):381-4. PubMed ID: 2155586
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence study of two formulations of etoposide in advanced lung cancer patients.
Li D; Liu L
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):474-9. PubMed ID: 25828637
[TBL] [Abstract][Full Text] [Related]
34. Etoposide protein binding in cancer patients.
Liu B; Earl HM; Poole CJ; Dunn J; Kerr DJ
Cancer Chemother Pharmacol; 1995; 36(6):506-12. PubMed ID: 7554043
[TBL] [Abstract][Full Text] [Related]
35. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives.
Aguilar Ponce JL; Flores-Picazo Y; Pérez-Urizar J; Castañeda-Hernández G; Zinser-Sierra JW; Dueñas-González A; Calderón-Flores E; Segura-Pacheco BA; de la Garza-Salazar J
Arch Med Res; 1999; 30(3):212-5. PubMed ID: 10427872
[TBL] [Abstract][Full Text] [Related]
36. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.
Chen CL; Rawwas J; Sorrell A; Eddy L; Uckun FM
Leuk Lymphoma; 2001 Jul; 42(3):317-27. PubMed ID: 11699396
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.
Würthwein G; Krümpelmann S; Tillmann B; Real E; Schulze-Westhoff P; Jürgens H; Boos J
Anticancer Drugs; 1999 Oct; 10(9):807-14. PubMed ID: 10587290
[TBL] [Abstract][Full Text] [Related]
38. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient.
el-Yazigi A; Ezzat A; Berry J; Raines DA; Yusuf A; al-Rawithi S; Legayada ES
J Clin Pharmacol; 2000 Feb; 40(2):153-60. PubMed ID: 10664921
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents.
Kato Y; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2003 Feb; 45(1):74-9. PubMed ID: 12654074
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]